The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal‐like breast cancer cells
FEBS Open Bio · 2023-02 · 13 (2) · 352-362
DOI: 10.1002/2211-5463.13547 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 16.01.2023. Verfasst von David Flores und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Texas-Rio Grande Valley, Edinburg, TX, USA. Hauptthemen laut MEDLINE: Glioblastoma, Breast Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of Food and Agriculture, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Basal‐like breast cancer (BBC) and glioblastoma multiforme (GBM) are poor‐prognosis cancers that lack effective targeted therapies and harbor embryonic stem gene expression signatures. Recently, our group and others found that forkhead box transcription factor FOXO1 promotes stem gene expression in BBC and GBM cell lines. Given the critical role of cancer stem cells in promoting cancer progression, we examined the impact of FOXO1 inhibition with AS1842856 (a cell‐permeable small molecule that directly binds to unphosphorylated FOXO1 protein to block transcriptional regulation) on BBC and GBM cell viability. We treated a set of BBC and GBM cancer cell lines with increasing concentrations of AS1842856 and found reduced colony formation. Treatment of BBC and GBM cancer cells with AS1842856 led to increases in FAS ( FAS cell surface death receptor ) and BIM ( BCL2L11 ) gene expression, as well as increased positivity for markers for apoptosis such as annexin V and propidium iodide. Treatment with another FOXO1 inhibitor AS1708727 or FOXO1 RNAi also led to FAS induction. This work is the first to show that targeting BBC and GBM with FOXO1 inhibition leads to apoptosis. These novel findings may ultimately expand the repertoire of therapies for poor‐prognosis cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, University of Texas-Rio Grande Valley, Edinburg, TX, USA.
ORCID-Profile: Megan Keniry
Förderung
- NIGMS NIH HHS
- National Institute of Food and Agriculture
- National Institute of General Medical Sciences
Zitieren
APA
Flores, D., Lopez, A., Udawant, S., Gunn, B., & Keniry, M. (2023). The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal‐like breast cancer cells. FEBS Open Bio, 13(2), 352-362. https://doi.org/10.1002/2211-5463.13547
Vancouver
Flores D, Lopez A, Udawant S, Gunn B, Keniry M. The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal‐like breast cancer cells. FEBS Open Bio. 2023;13(2):352-362. doi:10.1002/2211-5463.13547
BibTeX
@article{Flores2023,
author = {Flores, David and Lopez, Alma and Udawant, Shreya and Gunn, Bonnie and Keniry, Megan},
title = {The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal‐like breast cancer cells},
journal = {FEBS Open Bio},
year = {2023},
volume = {13},
number = {2},
pages = {352--362},
doi = {10.1002/2211-5463.13547}
}
EUVIMED